Parent Project España organized the 1st Congreso Nacional Duchenne which was held last 25th-27th May 2018 in Madrid. It aimed to help families and those affected gain access to the exchange of information and experiences in order to encourage mutual support and learn about the different aspects of Muscular Dystrophy of Duchenne and Becker.
The congress mainly analyzed the different therapeutic strategies that exist today, in addition to the key challenges and priorities to improve the quality of life in children, adolescents and adults with Muscular Dystrophy of Duchenne and Becker.
A panel of national and international experts, including SOM Biotech CEO Dr. Raúl Insa, were invited to provide knowledge about the treatments that are currently under study. Dr. Insa gave a discussion about repositioning of Utrophin, a naturally occurring protein that is functionally and structurally similar to dystrophin, which is essential for proper muscle function.
Dr. Insa during his presentation
Dr. Insa’s presentation title
SOM Biotech currently has a program in its pipeline indicated for Duchenne Muscular Dystrophy. SOM2201, the compound under study, is in the early preclinical phase, particularly the in vitro validation stage.
